You just read:

Aspyrian Therapeutics Inc. closes a $40M Series B financing to advance the precision targeted cancer therapy, RM-1929, to late stage clinical development in recurrent head and neck cancer and other cancer areas.

News provided by

Aspyrian Therapeutics Inc.

Mar 10, 2016, 06:00 ET